Filing Details
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) filed a Form 8-K with the Securities and Exchange Commission on August 13, 2026, disclosing a material event.
8k filedNASDAQ:DWTX
Dogwood Therapeutics, Inc. (DWTX) Reports Material Event to SEC
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) filed a Form 8-K with the Securities and Exchange Commission on August 13, 2026, disclosing a material event.
At publication ·
What changed
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) filed a Form 8-K with the SEC on August 13, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $1.98 with a market capitalization of $12.0 million.
- The specific nature of the material event was not disclosed in this article, though 8-K filings typically cover leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Dogwood Therapeutics, Inc.'s stock currently trades at $1.98 with a market capitalization of $12.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Dogwood Therapeutics, Inc.'s stock.
All SEC filings for Dogwood Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View DWTX Stock Page
Frequently Asked Questions
Where can I read DWTX's SEC filings?
Browse all filings on our DWTX SEC filings page.
What types of SEC filings does Dogwood Therapeutics, Inc. file?
Public companies like Dogwood Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.